Politician trade (House)

Eli Lilly (LLY)Rep. Marjorie Taylor Mrs Greene (GA14) disclosed a purchase $1K–$15K

Rep. Marjorie Taylor Mrs Greene (GA14) disclosed a purchase of Eli Lilly in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
3 days
Disclosure lag
Traded
Dec 24, 2024
Disclosed
Dec 27, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  2. Oct 30, 2024CongressDisclosed purchase of LLY — reported range $15,001 - $50,000
  3. Nov 8, 2024InsiderOfficer sold ~$723K of LLY shares in the open market
  4. Nov 8, 2024CongressDisclosed sale of LLY — reported range $15,001 - $50,000
  5. Nov 13, 2024FDAFDA drug approval: Verzenio
  6. Nov 14, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  7. Nov 19, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  8. Dec 9, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  9. Dec 10, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  10. Dec 11, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  11. Dec 12, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  12. Dec 13, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  13. Dec 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  14. Dec 18, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  15. Dec 20, 2024FDAFDA drug approval: Zepbound
  16. Dec 24, 2024 · this disclosureCongressDisclosed purchase of LLY — reported range $1,001 - $15,000

What came next

  1. Jan 8, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  2. Jan 15, 2025FDAFDA drug approval: Omvoh
  3. Jan 15, 2025FDAFDA drug approval: Omvoh
  4. Jan 21, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  5. Jan 22, 2025CongressDisclosed purchase of LLY — reported range $50,001 - $100,000
  6. Jan 27, 2025FDAFDA drug approval: Cyramza
  7. Feb 6, 2025Insider · 1 personInsiders: 22 sales (~$183.6M)
  8. Feb 10, 2025Insider · 1 personInsiders: 3 sales (~$4.3M)
  9. Feb 10, 2025CongressDisclosed sale of LLY — reported range $50,001 - $100,000
  10. Feb 13, 2025Insider · 1 personInsiders: 7 sales (~$31.2M)
  11. Feb 19, 2025Insider · 1 personInsiders: 4 sales (~$8.8M)
  12. Feb 20, 2025Insider · 1 personInsiders: 4 sales (~$12.9M)
  13. Feb 21, 2025Insider · 1 personInsiders: 17 sales (~$87.8M)
  14. Feb 24, 2025Insider · 1 personInsiders: 5 sales (~$14.6M)
  15. Apr 7, 2025FDAFDA drug approval: Cyramza
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Rep. Marjorie Taylor Mrs Greene (GA14)

The full history of Rep. Marjorie Taylor Mrs Greene (GA14) is on the profile page.

How this filing works

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data